Beckman Coulter

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35. 

The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year. 

A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.

Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent

The deal gives Beckman Coulter non-exclusive distribution rights in the US and Canada to the NGS library preparation kits for cell-free DNA in plasma.

The Beckman Coulter unit provides genomic sequencing solutions to healthcare businesses, governments, and academia around the world.

IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.

Following a beta evaluation of the system, a virology lab in Sheffield, UK, ran a workflow assessment and found improvements with the system.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.